CT‐derived simulations to predict outcomes in patients undergoing transcatheter aortic valve implantation with an ACURATE Neo2 valve the PRECISE‐TAVI cohort B trial

Thijmen W. Hokken,Philippe Nuyens,Claudio Ruffo,Rutger‐Jan Nuis,Joost Daemen,Isabella Kardys,Ricardo Budde,Nicola Buzzatti,Ole de Backer,Nicolas M. Van Mieghem
DOI: https://doi.org/10.1002/ccd.31194
IF: 2.3
2024-08-31
Catheterization and Cardiovascular Interventions
Abstract:Background Paravalvular leakage (PVL) and conduction disorders that require permanent pacemaker implantation (PPI) remain clinically relevant challenges after transcatheter aortic valve implantation (TAVI). Computed tomography‐based simulations may predict the risk of significant PVL and PPI. Aims To evaluate the feasibility and accuracy of preprocedural computer simulation with FEops HEARTguideTM to predict >trace PVL and PPI after TAVI with the self‐expanding supra‐annular ACURATE Neo2 transcatheter heart valve. Methods Prospective multicenter observational study that included consecutive patients undergoing TAVI with an ACURATE Neo2 valve. Computer simulations were performed before the TAVI procedure as part of the preprocedural planning. Follow‐up period for PPI and PVL was 30 days. Results Sixty‐five patients were included (median age 81 years (25th−75th percentile 77–84.5)). New left bundle branch block occurred in five patients (7.7%) and PPI in two patients (3%). Contact pressure index (CPI) was similar for patients with vs without new conduction disorders. Patients with PPI had numerically higher CPI than those without PPI (median CPI 20.0% (25th−75th percentile 15.0–25.0) vs. 13.0% (25th−75th percentile 5.5–18), p = 0.27). More than trace PVL occurred in 30%. Median PVL was significantly lower in patients with none‐trace PVL (3.2 mL/s [25th−75th percentile 2.2–5.0]), compared to mild PVL (5.2 mL/s [25th−75th percentile 3.2–10.3]) and moderate PVL (12.6 mL/s [25th−75th percentile 3.9–21.3])(p = 0.036). A simulated PVL‐cutoff of 9.65 mL/s identified patients with >trace PVL (AUC 0.70 (95% CI 0.55–0.85), sensitivity 42%, specificity 95%). Conclusion In our study FEops HEARTguideTM simulations identified patients at risk for >trace PVL with ACURATE Neo2 TAVI but not for PPI.
cardiac & cardiovascular systems
What problem does this paper attempt to address?